Camurus Shares Tumble 7% Following FDA Drug Rejection
Swedish pharmaceutical firm Camurus experienced a sharp 7% decline in share value after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its application for an acromegaly treatment. The regulatory setback highlights significant hurdles for the company’s expansion into the U.S. market, forcing investors to reassess the firm’s near-term growth outlook and clinical pipeline strategy.